Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 240

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease

Open access
Avgerinos, Konstantinos I., Ferrucci, Luigi, Kapogiannis, Dimitrios · 2021 · Ageing Research Reviews

Abstract

Objective: To investigate the effects of monoclonal antibodies against Aβ on cognition, function, amyloid PET and other biomarkers, as well as risk for amyloid-related imaging abnormalities (ARIA) and other adverse events, in Alzheimer’s disease (AD). Methods: Pubmed, Web of Science, ClinicalTrials.gov and gray literature were searched for phase III RCTs and random-effects meta-analyses were performed. Results: Seventeen studies (12,585 patients) were included. Antibodies statistically improved the cognitive outcomes ADAS-Cog {SMD = −0.06 [95% CI (−0.10; −0.02), I 2 = 0%]} and MMSE {SMD = 0.05 [95% CI (0.01; 0.09), I 2 = 0%]} by small effect sizes, but did not improve the cognitive/functional measure CDR-SOB {SMD = −0.03 [95% CI (−0.07; 0.01), I 2 = 18%]}. Moreover, antibodies decreased amyloid PET SUVR {SMD = −1.02 [95% CI (−1.70; −0.34), I 2 = 95%]} and CSF p181-tau {SMD = −0.87 [95% CI (−1.32; −0.43), I 2 = 89%]} by large effect sizes. They also increased risk for ARIA {RR = 4.30 [95% CI (2.39; 7.77), I 2 = 86%]} by a large effect size. Antibody effects on reducing amyloid PET SUVR were correlated with their effects on improving ADASCog (r = +0.68, p = 0.02). In subgroup analyses by individual drug, Aducanumab improved ADAS-Cog, CDRSOB, ADCS-ADL by small effect sizes and decreased amyloid PET SUVR and CSF p181-tau by large effect sizes. Solanezumab improved ADAS-Cog, MMSE by small effect sizes, and increased (improved) CSF Ab 1–40 levels by a moderate effect size. Bapineuzumab, Gantenerumab and Crenezumab did not improve any clinical outcomes. Bapineuzumab and Gantenerumab decreased CSF p181-tau by a small and large effect size, respectively. All drugs except Solanezumab increased ARIA risk. Conclusions: In this meta-analysis of phase III trials in AD, we found that monoclonalantibodies against Aβ induced clinical improvements of small effect size, biomarker improvements of large effect size, and increase in risk for the hallmark adverse event, ARIA, by a large effect size, when all drugs were pooled together. Among individual drugs, Aducanumab produced the most favorable effects followed by Solanezumab. These findings provide moderate support for the continuous development of anti-Aβ monoclonal antibodies as a treatment for AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.arr.2021.101339

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 240

Metadata

Authors
Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D.
Venue
Ageing Research Reviews
Publisher
Elsevier BV
Published
2021-07
Volume
68
Pages
101339
ISSN
1568-1637 (ISSN-L)
OpenAlex
W3146410983
Cited by
240
References
17
FWCI
7.50
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. https://app.cochat.ai/papers/10.1016/j.arr.2021.101339
The paper
Avgerinos, K. I., Ferrucci, L., & Kapogiannis, D. (2021). Effects of monoclonal antibodies against amyloid-β on clinical and biomarker outcomes and adverse event risks: A systematic review and meta-analysis of phase III RCTs in Alzheimer’s disease. Ageing Research Reviews. https://doi.org/10.1016/j.arr.2021.101339

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.